| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
Gemcitabine, a nucleoside analog, is frequently used to treat cancer; however, because cancer cells are highly sensitive to drug resistance, its effectiveness is restricted. Gemcitabine is shielded from several important anticancer pathways by the addition of a phosphoramidate motif. A number of prodrugs of gemcitabine phosphoramidate were prepared and tested for their ability to inhibit tumor growth in a variety of tumor cell lines. Of the compounds produced, NUC-1031 had strong effects in vitro.
|
|---|---|
| ln Vivo |
In a pancreatic xenograft model, ProTide significantly reduced tumor size and had less negative effects on body weight than the gemcitabine-treated group, suggesting a superior safety profile. The information clearly indicates that ProTides are stable in the presence of deaminases and do not depend on kinases or nucleoside transporters to function within tumor cells. ProTide NUC-1031 is presently progressing into a Phase I/II clinical investigation and has produced encouraging early efficacy signals, excellent security, and robust pharmacokinetic data showing notable increases in intracellular levels of gemcitabine triphosphate. Phosphoramidate compounds have the potential to be a significant source of novel, highly effective anticancer medications, resulting in a plethora of cutting-edge therapies intended to circumvent cancer resistance mechanisms and enhance patient outcomes [1].
|
| References |
| Molecular Formula |
C25H27F2N4O8P
|
|---|---|
| Molecular Weight |
580.4816
|
| Exact Mass |
580.153
|
| CAS # |
840506-29-8
|
| PubChem CID |
11169170
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.616
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
40
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@@H](C(=O)OCC1=CC=CC=C1)NP(=O)(OC[C@@H]2[C@H](C([C@@H](O2)N3C=CC(=NC3=O)N)(F)F)O)OC4=CC=CC=C4
|
| InChi Key |
NHTKGYOMICWFQZ-KKQYNPQSSA-N
|
| InChi Code |
InChI=1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)/t16-,19+,21+,23+,40?/m0/s1
|
| Chemical Name |
benzyl (2S)-2-[[[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
|
| Synonyms |
GTPL 7389 CPF-31 CPF31Acelarin NUC-1031 NUC 1031 NUC1031GTPL7389 GTPL-7389
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 36 mg/mL (~62.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7227 mL | 8.6136 mL | 17.2271 mL | |
| 5 mM | 0.3445 mL | 1.7227 mL | 3.4454 mL | |
| 10 mM | 0.1723 mL | 0.8614 mL | 1.7227 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02351765 | COMPLETED | Drug: Acelarin Drug: Cisplatin |
Ampullary Cancer Biliary Tract Cancer Cholangiocarcinoma Gallbladder Cancer |
The Christie NHS Foundation Trust | 2016-01 | Phase 1 |
| NCT03610100 | SUSPENDED | Drug: Acelarin Drug: Gemcitabine |
Pancreatic Acinar Carcinoma Pancreatic Neoplasms |
The Clatterbridge Cancer Centre NHS Foundation Trust | 2015-12 | Phase 2 Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
